News & Media / Press Releases

WBB Securities Acts as Financial Advisor to T2 Biosystems for $50 Million Credit Facility

January 5, 2017

WBB Securities acted as financial advisor to T2 Biosystems, Inc., a manufacturer of next generation diagnostic equipment, for a credit facility up to $50 million.

Continue Reading

WBB Securities Acts as Co-manager for $300 Million Public Offering for Sarepta Therapeutics

September 29, 2016

WBB Securities acted as co-manager to a transaction for Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics.

Continue Reading

John Nolan Joins WBB to Head Asset Management Team

September 2, 2016

WBB Securities, a leading investment management, investment banking, and equity research firm, announced today that John Nolan has joined the firm as Managing Director of WBB Asset Management[1] where he will also serve as a Portfolio Manager of a concentrated long/short portfolio that focuses on the biotechnology, specialty pharmaceutical and medical device sectors.

Continue Reading

WBB Securities Sponsors BioCentury’s Annual NewsMakers Conference

September 1, 2016

WBB Securities is a sponsor of this year’s NewsMakers in the Biotech Industry conference.

Continue Reading

WBB Securities Sponsors BioCentury’s 2016 Future Leaders Conference

March 1, 2016

WBB Securities is a sponsor of this year’s Future Leader’s conference.

Continue Reading

WBB Securities Acts as Co-manager for $100 Million in Public Offering for Cempra Pharmaceuticals

January 12, 2016

WBB Securities acted as co-manager to a transaction for Cempra Pharmaceuticals, a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics.

Continue Reading

WBB Securities Sponsors BioCentury’s Annual NewsMakers Conference

September 1, 2015

WBB Securities is a sponsor of this year’s NewsMakers in the Biotech Industry conference.

Continue Reading

WBB Securities Acts as Financial Advisor on $60 Million Loan for Navidea Biopharmaceuticals

May 11, 2015

WBB Securities acted as financial advisor to Navidea Biopharmaceuticals regarding a term loan with CRG (formerly Capital Royalty LP). Under the terms of the agreement, CRG will provide Navidea with initial funding of $50 million.

Continue Reading

WBB Securities Acts as Placement Agent for up to $25 Million in Equity Financing for Cytori Therapeutics

May 8, 2015

WBB Securities acted as placement agent to a transaction for Cytori Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing autologous cell therapies from adipose tissue to treat a variety of medical conditions.

Continue Reading

WBB Securities Sponsors BioCentury’s Future Leaders in the Biotech Industry Conference

March 20, 2015

Today WBB Securities sponsored BioCentury’s Future Leaders in the Biotech Industry conference held at the Millennium Broadway Hotel and Conference Center in New York City.

Continue Reading